J Breast Cancer.  2012 Sep;15(3):273-282. 10.4048/jbc.2012.15.3.273.

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ

• Reagan MR
• Seib FP
• McMillin D
• Sage EK
• Mitsiades
• Janes SM
• Ghobrial I
• Kaplan DL

• KMID: 2286452
• DOI: http://doi.org/10.4048/jbc.2012.15.3.273

Abstract

PURPOSE
Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.
METHODS
Implants were formed from porous, biocompatible silk scaffolds seeded with full length TRAIL-expressing MSCs (FLT-MSCs). under a doxycycline inducible promoter. In vitro studies with FLT-MSCs demonstrated TRAIL expression and antitumor effects on breast cancer cells. Next, FLT-MSCs were administered to mice using three administration routes (mammary fat pad co-injections, tail vein injections, and subcutaneous implantation on scaffolds).
RESULTS
In vitro cell-specific bioluminescent imaging measured tumor cell specific growth in the presence of stromal cells and demonstrated FLT-MSC inhibition of breast cancer growth. FLT-MSC implants successfully decreased bone and lung metastasis, whereas liver metastasis decreased only with tail vein and co-injection administration routes. Average tumor burden was decreased when doxycycline was used to induce TRAIL expression for co-injection and scaffold groups, as compared to controls with no induced TRAIL expression.
CONCLUSION
This implant-based therapeutic delivery system is an effective and completely novel method of anticancer therapy and holds great potential for clinical applications.

Keyword

Breast neoplasms; Mesenchymal stem cells; Tissue engineering; Tissue therapy; TNF-related apoptosis-inducing ligand

MeSH Terms

Adipose Tissue
Animals
Breast Neoplasms
Doxycycline
Liver
Lung
Mesenchymal Stromal Cells
Mice
Necrosis
Neoplasm Metastasis
Seeds
Silk
Stem Cells
Stromal Cells
Tissue Engineering
Tissue Therapy
TNF-Related Apoptosis-Inducing Ligand
Tumor Burden
Veins
Doxycycline
Silk
TNF-Related Apoptosis-Inducing Ligand

Figure

• 

  Figure 1 In vitro characterization of full length TRAIL-expressing MSCs (FLT-MSCs) and their impact on breast cancer cells. (A) TRAIL protein enzyme-linked immunosorbent assay (ELISA) of FLT-MSCs exposed to doxycycline (denoted as "dox") for denoted times. Cell specific-bioluminescence assay at 24 hours for MDA-MB-231 cell proliferation in cultures of cancer cells alone, cancer cells with FLT-MSCs, and co-culture with FLT-MSCs and doxycycline. Data is graphed as mean±standard error of the mean (SEM), n=3. (B) For direct co-culture imaging of FLT-MSCs and MDA-MB-231 breast cancer cells, breast cancer cells were grown alone, or with FLT-MSCs with and without doxycycline. After 48 hours of co-culture, MDA-MB-231 cells showed significant decreases in cell numbers in the FLT-MSC doxycycline group compared to the FLT-MSC no doxycycline group or the no MSC group. Statistics were done using an ANOVA and a Tukey's multiple comparison test. *p<0.001 (mean±SEM, n=4). TRAIL=tumor necrosis factor-related apoptosis-inducing ligand; MSC=mesenchymal stem cell; NS=not significant.

• 

  Figure 2 Scaffold design and characterization. (A) Timeline of in vitro scaffold screening experiment. (B) Representative live-dead confocal imaging of water-based (WB) or solvent-based (HFIP) scaffolds. Samples were pre-differentiated for 0, 3 or 4 weeks, (denoted as 0 wk, 3 wk, or 4 wk, respectively), re-seeded with DiD mesenchymal stem cells (MSCs), and imaged after 1 week. Cyan, DiD cells; Green, live cells; Red; dead cells and scaffold. All scale bars represent 300 µm. (C) Flow cytometric analysis of CD73 and (D) CD90 expression on DiD MSCs removed from array of scaffolds. No significant differences were found between groups using an ANOVA (mean±SEM, n=4).

• 

  Figure 3 Silk scaffold mesenchymal stem cell (MSC) retention after in vitro and in vivo culture. Live-dead confocal images of scaffolds (A) 5 days and (B) 16 days post-seeding demonstrating good viability in vitro of MSCs on scaffolds. Green, live cells; Red, dead cells and silk scaffold. Frozen section imaged on confocal microscope of full length TRAIL-expressing MSC (FLT-MSC)-seeded HFIP scaffolds removed (C) 2 weeks post-implantation of (D) 8 weeks post-implantation demonstrating retention of DiD FLT-MSCs in vivo. Red, DiD; Green, scaffold autofluorescence. Images made from z-stacked maximum or average projections. All scale bars equal in size and represent 300 µm. TRAIL=tumor necrosis factor-related apoptosis-inducing ligand.

• 

  Figure 4 DiD full length TRAIL-expressing MSCs (FLT-MSCs) fluorescence at 6 weeks after tumor inoculation for in vivo groups with doxycycline. (A) Co-injection group, (B) tail vein injection group, (C) implant group, and (D) breast cancer cells alone.

• 

  Figure 5 In vivo tumor growth and metastasis. (A) In vivo tumor growth assessed at weeks 1, 3, and 6 for the following mouse groups with and without doxycycline (Dox): breast cancer cells alone (BCCs), co-injection groups, tail vein injection groups, and Implant groups for mice. Statistics were done using a one-way ANOVA and a post-hoc Dunnett's test: *p<0.001; †0.001

Reference

1. Lee JH, Yim SH, Won YJ, Jung KW, Son BH, Lee HD, et al. Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J Korean Med Sci. 2007. 22:Suppl. S11–S16.

2. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res. 2010. 70:10044–10050.

3. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007. 449:557–563.

4. Reagan MR, Kaplan DL. Concise review. Mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011. 29:920–927.

5. Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe MF, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res. 2009. 69:8862–8867.

6. Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, et al. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011. 2:e121.

7. El-Deiry WS. Death Receptors in Cancer Therapy. 2005. Totowa: Humana Press;374.

8. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001. 61:3330–3338.

9. Müller N, Schneider B, Pfizenmaier K, Wajant H. Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun. 2010. 396:793–799.

10. Dörr J, Bechmann I, Waiczies S, Aktas O, Walczak H, Krammer PH, et al. Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci. 2002. 22:RC209.

11. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000. 6:564–567.

12. Wang Y, Rudym DD, Walsh A, Abrahamsen L, Kim HJ, Kim HS, et al. In vivo degradation of three-dimensional silk fibroin scaffolds. Biomaterials. 2008. 29:3415–3428.

13. Zhao X, Kim J, Cezar CA, Huebsch N, Lee K, Bouhadir K, et al. Active scaffolds for on-demand drug and cell delivery. Proc Natl Acad Sci USA. 2011. 108:67–72.

14. Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009. 8:151–158.

15. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009. 69:4134–4142.

16. Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res. 2007. 67:10304–10308.

17. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010. 16:483–489.

18. Bhardwaj N, Nguyen QT, Chen AC, Kaplan DL, Sah RL, Kundu SC. Potential of 3-D tissue constructs engineered from bovine chondrocytes/silk fibroin-chitosan for in vitro cartilage tissue engineering. Biomaterials. 2011. 32:5773–5781.

19. Lü K, Xu L, Xia L, Zhang Y, Zhang X, Kaplan DL, et al. An ectopic study of apatite-coated silk fibroin scaffolds seeded with AdBMP-2-modified canine bMSCs. J Biomater Sci Polym Ed. 2012. 23:509–526.

20. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells. 2009. 27:1548–1558.

21. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005. 5:591–602.

22. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009. 5:54–63.

23. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011. 20:370–383.

24. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010. 28:1527–1533.